Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Leading synthetic biologists have shared hard-won lessons from their decade-long quest to build the world's first synthetic ...

Instead of a single, massive LLM, Nvidia's new 'orchestration' paradigm uses a small model to intelligently delegate tasks to ...

In interviews with Ars Technica this week, OpenAI employees revealed the extent to which the company now relies on its own AI ...

Dr. Najat Khan of Recursion shared insights into the creation of the Microglia Map and what it could mean for future drug discovery.

Artificial intelligence and machine learning are reshaping how investors build and maintain portfolios. These tools bring ...

Amazon Q Developer is a useful AI-powered coding assistant with chat, CLI, Model Context Protocol and agent support, and AWS ...

Yet too many CEOs still believe they can solve the problem by outbidding competitors for scarce talent. They can’t. The AI skills gap isn’t a hiring problem. It’s a systems problem.

Learn how Excel functions can act as data using LAMBDA, LET, and BYROW, so you reuse logic and cut formula edits.

Stablecoin supply growth reflects genuine capital inflows, making it the only metric for predicting crypto market movements.